Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 48

1.

Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo.

Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, Yndestad S, de Faveri E, Karlsen BO, Wedge DC, Akslen LA, Lilleng PK, Løkkevik E, Lundgren S, Østenstad B, Risberg T, Mjaaland I, Aas T, Lønning PE.

Mol Oncol. 2015 May 8. pii: S1574-7891(15)00096-4. doi: 10.1016/j.molonc.2015.04.008. [Epub ahead of print]

2.

Clinical outcome with correlation to disseminated tumor cell (DTC) status after DTC-guided secondary adjuvant treatment with docetaxel in early breast cancer.

Naume B, Synnestvedt M, Falk RS, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Sommer HH, Sætersdal AB, Rypdal MC, Bendigtsen Schirmer C, Wist EA, Borgen E.

J Clin Oncol. 2014 Dec 1;32(34):3848-57. doi: 10.1200/JCO.2014.56.9327. Epub 2014 Nov 3.

PMID:
25366688
3.

Disseminated tumor cells as selection marker and monitoring tool for secondary adjuvant treatment in early breast cancer. Descriptive results from an intervention study.

Synnestvedt M, Borgen E, Wist E, Wiedswang G, Weyde K, Risberg T, Kersten C, Mjaaland I, Vindi L, Schirmer C, Nesland JM, Naume B.

BMC Cancer. 2012 Dec 22;12:616. doi: 10.1186/1471-2407-12-616.

4.

Persistence of disseminated tumor cells after neoadjuvant treatment for locally advanced breast cancer predicts poor survival.

Mathiesen RR, Borgen E, Renolen A, Løkkevik E, Nesland JM, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Kvalheim G, Lønning PE, Naume B.

Breast Cancer Res. 2012 Aug 14;14(4):R117. doi: 10.1186/bcr3242.

5.

Low expression levels of ATM may substitute for CHEK2 /TP53 mutations predicting resistance towards anthracycline and mitomycin chemotherapy in breast cancer.

Knappskog S, Chrisanthar R, Løkkevik E, Anker G, Østenstad B, Lundgren S, Risberg T, Mjaaland I, Leirvaag B, Miletic H, Lønning PE.

Breast Cancer Res. 2012 Mar 15;14(2):R47.

6.

Predictive and prognostic impact of TP53 mutations and MDM2 promoter genotype in primary breast cancer patients treated with epirubicin or paclitaxel.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Skjønsberg G, Aas T, Schlichting E, Fjösne HE, Nysted A, Lillehaug JR, Lønning PE.

PLoS One. 2011 Apr 27;6(4):e19249. doi: 10.1371/journal.pone.0019249.

7.

CHEK2 mutations affecting kinase activity together with mutations in TP53 indicate a functional pathway associated with resistance to epirubicin in primary breast cancer.

Chrisanthar R, Knappskog S, Løkkevik E, Anker G, Østenstad B, Lundgren S, Berge EO, Risberg T, Mjaaland I, Maehle L, Engebretsen LF, Lillehaug JR, Lønning PE.

PLoS One. 2008 Aug 26;3(8):e3062. doi: 10.1371/journal.pone.0003062.

8.

Medical students' cognitive and affective attitudes towards learning and using communication skills--a nationwide cross-sectional study.

Anvik T, Grimstad H, Baerheim A, Bernt Fasmer O, Gude T, Hjortdahl P, Holen A, Risberg T, Vaglum P.

Med Teach. 2008;30(3):272-9. doi: 10.1080/01421590701784356.

PMID:
18484454
9.

Curriculum factors influencing knowledge of communication skills among medical students.

Baerheim A, Hjortdahl P, Holen A, Anvik T, Fasmer OB, Grimstad H, Gude T, Risberg T, Vaglum P.

BMC Med Educ. 2007 Oct 10;7:35.

10.

Assessing medical students' attitudes towards learning communication skills--which components of attitudes do we measure?

Anvik T, Gude T, Grimstad H, Baerheim A, Fasmer OB, Hjortdahl P, Holen A, Risberg T, Vaglum P.

BMC Med Educ. 2007 Mar 30;7:4.

11.

The novel p21 polymorphism p21G251A is associated with locally advanced breast cancer.

Staalesen V, Knappskog S, Chrisanthar R, Nordgard SH, Løkkevik E, Anker G, Ostenstad B, Lundgren S, Risberg T, Mjaaland I, Gram IT, Kristensen VN, Børresen-Dale AL, Lillehaug JR, Lønning PE.

Clin Cancer Res. 2006 Oct 15;12(20 Pt 1):6000-4.

12.

Changes in bone and lipid metabolism in postmenopausal women with early breast cancer after terminating 2-year treatment with exemestane: a randomised, placebo-controlled study.

Geisler J, Lønning PE, Krag LE, Løkkevik E, Risberg T, Hagen AI, Schlichting E, Lien EA, Ofjord ES, Eide GE, Polli A, di Salle E, Paolini J.

Eur J Cancer. 2006 Nov;42(17):2968-75. Epub 2006 Sep 11.

PMID:
16963261
13.

Comparing self-reported communication skills of medical students in traditional and integrated curricula: a nationwide study.

Gude T, Baerheim A, Holen A, Anvik T, Finset A, Grimstad H, Hjortdahl P, Risberg T, Vaglum P.

Patient Educ Couns. 2005 Sep;58(3):271-8.

PMID:
16061342
14.
15.

[Should complementary therapies be offered in hospitals?].

Risberg T, Bremnes Y, Kolstad A, Holte H, Wist E, Mella O, Klepp O.

Tidsskr Nor Laegeforen. 2004 Dec 2;124(23):3078-80. Norwegian.

16.

Oral capecitabine in anthracycline- and taxane-pretreated advanced/metastatic breast cancer.

Wist EA, Sommer HH, Ostenstad B, Risberg T, Bremnes Y, Mjaaland I.

Acta Oncol. 2004;43(2):186-9.

PMID:
15163168
17.

Weekly one-hour paclitaxel as first-line chemotherapy for metastatic breast cancer.

Wist EA, Sommer HH, Ostenstad B, Risberg T, Fjaestad K.

Acta Oncol. 2004;43(1):11-4.

PMID:
15068314
18.

Knowledge of and attitudes toward complementary and alternative therapies; a national multicentre study of oncology professionals in Norway.

Risberg T, Kolstad A, Bremnes Y, Holte H, Wist EA, Mella O, Klepp O, Wilsgaard T, Cassileth BR.

Eur J Cancer. 2004 Mar;40(4):529-35.

PMID:
14962719
19.

Use of complementary and alternative therapies: a national multicentre study of oncology health professionals in Norway.

Kolstad A, Risberg T, Bremnes Y, Wilsgaard T, Holte H, Klepp O, Mella O, Wist E.

Support Care Cancer. 2004 May;12(5):312-8. Epub 2004 Feb 6.

PMID:
14767750
20.
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk